Title: Insulin-like modulation of Akt/FoxO signaling by copper ions is independent of insulin receptor.
Journal: Archives of biochemistry and biophysics 20140915
Title: Acute and long-term effects of arsenite in HepG2 cells: modulation of insulin signaling.
Journal: Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine 20140401
Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters 20130801
Title: Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.
Journal: Blood 20121018
Title: Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptor.
Journal: Breast cancer research and treatment 20120501
Title: Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines.
Journal: Molecular cancer therapeutics 20120201
Title: A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer.
Journal: Cancer research 20111101
Title: The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma.
Journal: Gynecologic oncology 20111001
Title: 18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110515
Title: Potent and selective cyclohexyl-derived imidazopyrazine insulin-like growth factor 1 receptor inhibitors with in vivo efficacy.
Journal: Bioorganic & medicinal chemistry letters 20110215
Title: Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer.
Journal: Molecular cancer therapeutics 20101001
Title: Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20100615
Title: Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family of receptor tyrosine kinases.
Journal: Bioorganic & medicinal chemistry letters 20100415
Title: Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor.
Journal: Future medicinal chemistry 20090901
Title: A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo.
Journal: Molecular cancer therapeutics 20070801
Title: Mulvihill MJ, et al. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and IR. Future Med Chem. 2009 Sep;1(6):1153-71.
Title: McKinley ET, et al. 18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer. Clin Cancer Res. 2011 May 15;17(10):3332-40.
Title: Li W, et al. Effectiveness of inhibitor rapamycin, saracatinib, linsitinib and JNJ-38877605 against human prostate cancer cells. Int J Clin Exp Med. 2015 Apr 15;8(4):6563-7.
